

Non Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 1st Line







Good Performance Status

EGFR TKI Naive
EGFR Mutated

[LUN0066](#)
[Phase Ib Erlotinib &
Mometinib in Tx of
EGFR, Mutated
EGFR TKI Naive
Metastatic NSCLC](#)

PI: Wakelee
Gilead Sciences

KEY

- | | | |
|---|--|---|
|  Pending |  Optional Path |  Extension Study |
|  Open for Enrollment | Link Trial Posting | |
|  Observational Study |  Enrollment on Hold | |